Primary salivary hyperplasia (also known as primary salivary overflow, salivation, etc.) refers to a significant increase in salivary secretion without obvious causative factors, which often leads to involuntary salivary flow from the corners of the mouth, saliva splashing when speaking, frequent swallowing or vomiting, seriously affecting life, work and social life, leading to depression and low self-esteem. It can also lead to choking and coughing when eating and speaking, and even lead to aspiration pneumonia. The current treatment methods for primary salivary hyperplasia are: 1, parasympathetic blocker drug therapy, but the drug effect is short and has side effects, can not be used for a long time; 2, radiation to reduce gland secretion, but easy to lead to tissue necrosis and dry mouth and other complications; 3, surgery to remove the main saliva-secreting glands (submandibular gland or parotid gland) or ligation of the duct, but will leave scars in the jaw face, produce depression However, it may leave scars, create depressions in the maxillofacial area, cause facial nerve damage and lead to facial palsy or complications such as postoperative swelling and pain of the gland, cysts and stone formation. In response to the shortcomings of the above treatment, in recent years, our department has applied a new method, namely, “transoral severing of the parasympathetic fibers of the submandibular ganglion” to treat primary salivary hyperplasia with good results. The objective evaluation efficiency of this method for primary salivary hyperplasia was 96.78% and the subjective evaluation efficiency was 93.55%, while no significant complications were observed. Therefore, the new method is simple, easier, safer, and more effective than the aforementioned traditional methods.